These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33589519)

  • 1. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
    Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
    Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2.
    Song Z; Gong B; Qu T; Chen Y; Zhao G; Jin Y; Zhao Q
    Biomed Pharmacother; 2024 Aug; 177():117126. PubMed ID: 38996706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
    Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
    Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
    Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J
    Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
    Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
    Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
    Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
    Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9-Mediated Bioluminescent Tagging of Endogenous Proteins by Fluorescent Protein-Assisted Cell Sorting.
    Hawley RG; Hawley TS
    Methods Mol Biol; 2024; 2779():273-286. PubMed ID: 38526790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
    Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
    Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition.
    Gonzalez Curto G; Der Vartanian A; Frarma YE; Manceau L; Baldi L; Prisco S; Elarouci N; Causeret F; Korenkov D; Rigolet M; Aurade F; De Reynies A; Contremoulins V; Relaix F; Faklaris O; Briscoe J; Gilardi-Hebenstreit P; Ribes V
    PLoS Genet; 2020 Nov; 16(11):e1009164. PubMed ID: 33175861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
    Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS
    Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyosarcomas are oncogene addicted to the activation of AVIL.
    Xie Z; Janczyk PL; Shi X; Wang Q; Singh S; Cornelison R; Xu J; Mandell JW; Barr FG; Li H
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2118048119. PubMed ID: 37146302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
    Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
    Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhabdomyosarcoma fusion oncoprotein initially pioneers a neural signature in vivo.
    Kucinski J; Tallan A; Taslim C; Wang M; Cannon MV; Silvius KM; Stanton BZ; Kendall GC
    bioRxiv; 2024 Jul; ():. PubMed ID: 39071299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entinostat as a combinatorial therapeutic for rhabdomyosarcoma.
    Chauhan S; Lian E; Habib I; Liu Q; Anders NM; Bugg MM; Federman NC; Reid JM; Stewart CF; Cates T; Michalek JE; Keller C
    Sci Rep; 2024 Aug; 14(1):18936. PubMed ID: 39147820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel PAX3::MAML3 Fusion Identified in Alveolar Rhabdomyosarcoma, Using DNA Methylation Profiling to Expand the Genetic Spectrum of "Fusion-Positive" Cases.
    Dermawan JK; Malik F; Gross JM; Baraban E; Pratilas C; Mneimneh W; Trucco M; Sun W; Barr FG; D'Almeida Costa F; Fritchie KJ
    Mod Pathol; 2024 Aug; 37(11):100594. PubMed ID: 39147032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming Growth Factor Beta and Alveolar Rhabdomyosarcoma: A Challenge of Tumor Differentiation and Chemotherapy Response.
    Bhushan B; Iranpour R; Eshtiaghi A; da Silva Rosa SC; Lindsey BW; Gordon JW; Ghavami S
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells.
    Yoshida H; Sato-Dahlman M; Hajeri P; Jacobsen K; Koodie L; Yanagiba C; Shanley R; Yamamoto M
    Transl Oncol; 2021 Feb; 14(2):100997. PubMed ID: 33338875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets.
    Zhang S; Wang J; Liu Q; McDonald WH; Bomber ML; Layden HM; Ellis J; Borinstein SC; Hiebert SW; Stengel KR
    Mol Cell; 2022 Dec; 82(23):4428-4442.e7. PubMed ID: 36395771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biphenotypic sinonasal sarcoma with PAX3/FOXO1 fusion.
    Tosun I; Karabulut MH; Yilmaz I; Cırık AA; Sahin O
    Pol J Pathol; 2023; 74(4):282-285. PubMed ID: 38477090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.